ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Is Up 5.2% After GD3 Neurology Trial Win - Has The Bull Case Changed?
Sanofi recently reported that its investigational oral therapy venglustat met the primary and most key secondary endpoints in the phase 3 LEAP2MONO study for type 3 Gaucher disease, showing statistically significant neurological benefits versus enzyme replacement therapy and prompting plans for global regulatory filings.
The readout is particularly important because it targets neurological manifestations of GD3, an area with no approved treatments despite long-standing systemic...